While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...
Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...
With a majority vote by the Senate Finance Committee, Robert F. Kennedy Jr's nomination for health secretary is pushed to a ...
World Cancer Day also marks the start of the ‘United by Unique’ campaign, which seeks to highlight how each person’s journey ...
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...
A new meta-analysis adds to the body of literature promoting the benefits of exercise for patients with cancer.
The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...
Insurance coverage of preventive care is on the line as Braidwood Management v Becerra moves to the Supreme Court this year.
February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you ...
Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...
The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback